---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-056018"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:21:53.360923+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Protagonist Q1 net loss $33.7M; positive Phase 2b data for JNJ-2113; cash runway to 2025

## Summary
- Net loss $33.7M ($0.67/share) vs $20.9M loss in Q1 2022; license revenue zero (prior year $25.7M milestone).
- Positive Phase 2b FRONTIER 1 topline data for JNJ-2113 in psoriasis: PASI-75 met across all dose groups vs placebo.
- Phase 2 REVIVE rusfertide data: 69.2% responders vs 18.5% placebo (p=0.0003); phlebotomy free 92.3% vs placebo.
- Closed public offering of 5.75M shares at $20 each; net proceeds $108.1M; cash runway now through end of 2025.
- Cash and marketable securities $230.8M; R&D expenses $27.4M (down from $36.3M); G&A $8.6M (down from $10.5M).

## SEC filing metadata
- accession: 0001104659-23-056018
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465923056018/0001104659-23-056018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465923056018/tm2314649d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-056018
- JSON: https://secwatch.observer/filing/0001104659-23-056018.json
- Plain text: https://secwatch.observer/filing/0001104659-23-056018.txt

## Key facts
- Earnings Releases
  Protagonist Therapeutics, Inc reported the first quarter ended March 31, 2023 results: revenue zero.
  - Period: the first quarter ended March 31, 2023
  - Revenue: zero
  - Result: reported results
  source text: License and collaboration revenue for the first quarter 2023 was zero, as compared to $25.7 million for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465923056018/0001104659-23-056018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.